Fulcrum Therapeutics (FULC) Accumulated Depreciation & Amortization (2019 - 2025)
Historic Accumulated Depreciation & Amortization for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $15.3 million.
- Fulcrum Therapeutics' Accumulated Depreciation & Amortization rose 1016.71% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 1016.71%. This contributed to the annual value of $14.3 million for FY2024, which is 1173.2% up from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Accumulated Depreciation & Amortization is $15.3 million, which was up 1016.71% from $15.0 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $15.3 million in Q3 2025 and a low of $6.7 million during Q1 2021
- Over the past 5 years, Fulcrum Therapeutics' median Accumulated Depreciation & Amortization value was $11.8 million (recorded in 2023), while the average stood at $11.4 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first soared by 5482.61% in 2021, then surged by 1016.71% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $8.3 million in 2021, then grew by 28.94% to $10.7 million in 2022, then grew by 19.68% to $12.8 million in 2023, then rose by 11.73% to $14.3 million in 2024, then rose by 7.32% to $15.3 million in 2025.
- Its Accumulated Depreciation & Amortization was $15.3 million in Q3 2025, compared to $15.0 million in Q2 2025 and $14.6 million in Q1 2025.